ArticleFrontiers in oncology2021

PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China.

Qiao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.